Science

Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection

Yakup Ergün/obdh.com.tr

Jan 28, 2025, 17:24

Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a paper he co-authored with colleagues published in Expert Review of Molecular Diagnostics:

“In the present day, when we have learned that KRAS mutations can be targeted, I was reminded of our research on the selection of backbone chemotherapy.

We had found that irinotecan was superior to oxaliplatin in patients with codon 12 mutations in metastatic KRAS-mutant CRC.”

“KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer”

Authors: Yakup Ergun, Yusuf Acikgoz, Oznur Bal, Gokhan Ucar, Merve Dirikoc, Eda Caliskan Yildirim, Nadiye Akdeniz, Dogan Uncu.

Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection

More posts featuring Yakup Ergün.

cancer CRC Dogan Uncu Eda Caliskan Yildirim Gokhan Ucar KRAS-mutant CRC Merve Dirikoc Nadiye Akdeniz OncoDaily Oncology Oznur Bal Yakup Ergün Yusuf Acikgoz

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial